Drug profile · INN
mifamurtide
MEPACT
mifamurtide (MEPACT) is a nucleotide-binding oligomerization domain-containing protein 2 other. Associated with S.A..
EMA: approved Antineoplastic and immunomodulating agents (L03) L03AX15
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — mifamurtide
- Class
- Antineoplastic and immunomodulating agents (L03)
- Route
- —
- Patents
- 0
- Programs
- 2
- Data quality
- 0.89
Quick answer
mifamurtide (MEPACT) is a nucleotide-binding oligomerization domain-containing protein 2 other. Associated with S.A..
Key facts
INN mifamurtide
Brand MEPACT
Mechanism Nucleotide-binding oligomerization domain-containing protein 2 other
Target Nucleotide-binding oligomerization domain-containing protein 2
Therapeutic class Antineoplastic and immunomodulating agents (L03)
ATC code L03AX15
Originator S.A.
Mechanism of action
Nucleotide-binding oligomerization domain-containing protein 2 other
Primary target: Nucleotide-binding oligomerization domain-containing protein 2
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is mifamurtide?
mifamurtide (MEPACT) is a nucleotide-binding oligomerization domain-containing protein 2 other. Associated with S.A..
What is the brand name for mifamurtide?
MEPACT is a marketed brand name for mifamurtide. Check FDA Drugs@FDA for the current US label holder and prescribing information.